A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof

Details for Australian Patent Application No. 2001264565 (hide)

Owner Ludwig Institute for Cancer Research

Inventors Achen, Marc G.; Stacker, Steven

Agent Griffith Hack

Pub. Number AU-B-2001264565

PCT Pub. Number WO01/82870

Priority 60201421 03.05.00 US

Filing date 3 May 2001

Wipo publication date 12 November 2001

Acceptance publication date 7 December 2006

International Classifications

C07K 14/52 (2006.01) Peptides having more than 20 amino acids

A61K 38/18 (2006.01) Medicinal preparations containing peptides - Growth factors

A61K 38/19 (2006.01) Medicinal preparations containing peptides - Cytokines

Event Publications

7 December 2006 Application Accepted

  Published as AU-B-2001264565

5 April 2007 Standard Patent Sealed

7 August 2008 Assignment Registered

  Ludwig Institute for Cancer Research The patent has been assigned to Vegenics Limited

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001264566-Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors

2001264564